The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.

Current Opinion in Oncology
Kevin D Courtney, Mary-Ellen Taplin

Abstract

The review examines recent advances in second-line hormonal therapy for the treatment of castrate-resistant prostate cancer (CRPC). Recent data highlight the continued importance of androgen signaling in CRPC. These findings have spurred the development of novel inhibitors of adrenal and intra-tumoral androgen synthesis and novel androgen signaling inhibitors with activity in CRPC. In the past year abiraterone acetate, a CYP17 (17α-hydroxylase/17, 20 lyase) inhibitor, received US FDA approval for use in the treatment of metastatic CRPC in patients previously treated with docetaxel. Additionally, the novel androgen signaling inhibitor MDV3100 has been reported to confer a survival advantage compared to placebo in the same patient population. Here we review the scientific rationale for targeting androgen signaling in CRPC and the recent pivotal trials that support the use of novel second-line hormonal therapies. Additionally, we summarize ongoing preclinical and clinical efforts to ascertain and overcome mechanisms of resistance. Novel inhibitors of extra-gonadal androgen synthesis and androgen receptor function demonstrate the continued importance of androgen signaling in CRPC. These agents have improved clinical outcomes for pa...Continue Reading

References

May 1, 1983·The Journal of Clinical Investigation·D S LooseD Feldman
May 25, 1995·The New England Journal of Medicine·M E TaplinS P Balk
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mary-Ellen TaplinUNKNOWN Cancer and Leukemia Group B Study 9663
Jan 2, 2004·Nature Medicine·Charlie D ChenCharles L Sawyers
Feb 5, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James L MohlerFrank S French
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric J SmallNicholas J Vogelzang
Jan 1, 1952·Proceedings of the National Academy of Sciences of the United States of America·C Huggins, D M Bergenstal
Jul 23, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gerhardt AttardJohann S de Bono
Feb 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel C DanilaHoward I Scher
Feb 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alison H M ReidJohann S de Bono
Feb 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles J RyanEric J Small
Mar 25, 2010·The Prostate·Laura TerraneoMichele Samaja
Apr 20, 2010·Lancet·Howard I ScherUNKNOWN Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium
Jul 21, 2010·The Journal of Clinical Investigation·Shihua SunStephen R Plymate
Jul 22, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Masuo YamaokaMasami Kusaka
May 25, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ming YangPhilip W Kantoff
May 27, 2011·The New England Journal of Medicine·Johann S de BonoUNKNOWN COU-AA-301 Investigators
Jun 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Charles J RyanEric J Small
Jun 30, 2011·Endocrine-related Cancer·Changmeng Cai, Steven P Balk
Jul 29, 2011·Proceedings of the National Academy of Sciences of the United States of America·Kai-Hsiung ChangNima Sharifi
Aug 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elahe A MostaghelR Bruce Montgomery
Aug 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles J Ryan, Donald J Tindall

❮ Previous
Next ❯

Citations

Aug 4, 2012·PLoS Neglected Tropical Diseases·Shamila S GunatillekeLarissa M Podust
Dec 3, 2013·Critical Reviews in Oncology/hematology·Shouki BazarbashiAli Shamseddine
Feb 26, 2013·The Journal of Steroid Biochemistry and Molecular Biology·Andrzej SlominskiRobert C Tuckey
Jun 25, 2013·The Journal of Steroid Biochemistry and Molecular Biology·Isabel HeideggerHelmut Klocker
Apr 23, 2017·Journal of Labelled Compounds & Radiopharmaceuticals·Xuehai PangYuanwei Chen
Aug 14, 2013·Endocrine Reviews·Andrzej T SlominskiJean Rivier
Oct 23, 2014·Chemical Reviews·Jun Yong ChoiWilliam R Roush

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biosynthetic Transformations

Biosyntheic transformtions are multi-step, enzyme-catalyzed processes where substrates are converted into more complex products in living organisms. Simple compounds are modified, converted into other compounds, or joined together to form macromolecules. Discover the latest research on biosynthetic transformations here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Related Papers

Current Opinion in Oncology
Eric G Bluemn, Peter S Nelson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Eleni EfstathiouChristopher J Logothetis
The New England Journal of Medicine
J S De BonoCOU-AA-301 Investigators
© 2022 Meta ULC. All rights reserved